Last reviewed · How we verify
Sufentanil Bolus
Sufentanil Bolus is a Opioid agonist Small molecule drug developed by University of Nebraska. It is currently FDA-approved for Acute pain management, Procedural sedation and analgesia, Perioperative analgesia. Also known as: Sufentanil.
Sufentanil is a potent opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia and sedation.
Sufentanil Bolus is a small molecule that acts as a mu opioid receptor agonist. It is used in medical procedures, including laparoscopic surgery, and has been studied in various clinical trials for conditions such as postpartum depression and pain management.
At a glance
| Generic name | Sufentanil Bolus |
|---|---|
| Also known as | Sufentanil |
| Sponsor | University of Nebraska |
| Drug class | Opioid agonist |
| Target | Mu (μ) opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management, Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Sufentanil acts as a selective agonist at mu (μ) opioid receptors, which are distributed throughout the brain and spinal cord. This binding modulates pain perception and produces sedation by affecting neurotransmitter release and neuronal signaling. As a bolus formulation, it provides rapid onset of action for acute pain management and procedural sedation.
Approved indications
- Acute pain management
- Procedural sedation and analgesia
- Perioperative analgesia
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Nausea
- Dizziness
- Chest wall rigidity
Key clinical trials
- Cardiac Index and General Anesthesia Without Opioid. (PHASE2, PHASE3)
- Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery in Gynecologic Oncology (NA)
- The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Laparoscopic Surgery (NA)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Hemorrhoid Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sufentanil Bolus CI brief — competitive landscape report
- Sufentanil Bolus updates RSS · CI watch RSS
- University of Nebraska portfolio CI
Frequently asked questions about Sufentanil Bolus
What is Sufentanil Bolus?
How does Sufentanil Bolus work?
What is Sufentanil Bolus used for?
Who makes Sufentanil Bolus?
Is Sufentanil Bolus also known as anything else?
What drug class is Sufentanil Bolus in?
What development phase is Sufentanil Bolus in?
What are the side effects of Sufentanil Bolus?
What does Sufentanil Bolus target?
Related
- Drug class: All Opioid agonist drugs
- Target: All drugs targeting Mu (μ) opioid receptor
- Manufacturer: University of Nebraska — full pipeline
- Therapeutic area: All drugs in Pain Management, Anesthesia
- Indication: Drugs for Acute pain management
- Indication: Drugs for Procedural sedation and analgesia
- Indication: Drugs for Perioperative analgesia
- Also known as: Sufentanil
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing